Cross-border biotech Anji Pharma closed $70 million in Series B funding to advance a drug pipeline that includes metabolic and cancer drugs. The biotech’s business model of finding promising drugs and forming subsidiaries to develop them is similar to approaches taken by Roivant Sciences and BridgeBio Pharma, among others.
The Beijing company said it selected the United Arab Emirates because of its ethnic diversity, which will enable it to determine the feasibility of taking its program global. It claims that its study is the first Phase III inactivated vaccine trial, but another Chinese firm has also launched one in Brazil.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Beijing-based company said its vaccine had produced immune responses in participants, though it remains unclear whether it will prevent infection with SARS-CoV-2, or for how long.
Data from a suspended Phase III trial in China of Gilead's remdesivir produced a negative result. An executive cautioned that the trial's low enrollment meant it had insufficient statistical power to draw any conclusions, but an analyst reiterated the view that the drug's pandemic role is overestimated.
Shares of the company were down more than 3%, though its studies are ongoing. An analyst wrote that the lack of revealed severe-disease suggested that any benefits observed were inconclusive. Compassionate use data last week were not definitive, but suggested potential benefit.
Although it didn't disclose data for the study, the Beijing-based biotech company said it planned to seek Chinese approval for tislelizumab in first-line, non-squamous non-small-cell lung cancer. The drug is in several Phase III trials, including in the U.S.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Phase III study showed that BeiGene's Brukinsa outperformed AbbVie and J&J's Imbruvica on safety. An analyst wrote that FDA approval on that basis is unlikely, but off-label prescribing is possible. Brukinsa won approval for another blood cancer last month.
Under the deal, BeiGene will help Amgen commercialize its oncology drugs in China, while Amgen will acquire slightly more than one-fifth of the Beijing-based firm. BeiGene will also participate in R&D efforts on 20 drugs in Amgen's oncology portfolio.
Celgene had been expected to hand the PD-1 checkpoint inhibitor tislelizumab back over to the Chinese company due to its $74 billion acquisition by Bristol-Myers Squibb, which already has its own well-established PD-1 inhibitor, Opdivo.
While zanubrutinib showed a higher response rate in the same mantle cell lymphoma setting for which Imbruvica is approved, the Phase II study enrolled younger, less heavily pretreated patients than those in Imbruvica's pivotal trial.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Everybody and their brother would seem to have a digital health app tied to some form of artificial intelligence algorithm. But for a search engine business, it makes sense.
Chinese cancer immunotherapy player BeiGene just filed a $100 IPO with the U.S. Securities Exchange Commission to advance its clinical pipeline of BTK, RAF and PARP inhibitors.
Qualcomm Wireless Reach and The George Institute are collaborating to set up a center for mHealth innovation in China to satisfy a government goal to improve access to healthcare in the country. The center will be located at The George Institute for Global Health at Peking University Health Science Center and will be funded by […]
Obama will be heading to Beijing for the Asia-Pacific Economic Cooperation summit in November, and the Chinese government is essentially putting together a concerted effort to shove all of the clutter in a closet before the guests arrive. The infamous smog in Beijing is a health concern for the people who live there, in fact […]
Two St. Jude Medical (NYSE:STJ) strategies intersected on Tuesday as the maker of new innovative medical devices unveiled the latest of its advanced technology centers in one of the world’s most coveted med-tech markets: China. The St. Jude Medical Advanced Technology Center Asia Pacific officially opened on Tuesday morning in Beijing. It’s the latest of […]